Published by Broadly VICE AU, February 17, 2017
by Rebecca Kamm and Sammi Taylor
There were high hopes the arrival of “pink Viagra” would herald a blissful new age of pharmaceutically enhanced female libidos. But the uptake of flibanserin, approved by the FDA in 2015 for the treatment of low sex drive in women (also known as hypoactive sexual desire disorder), has failed to sparked the revolution it might have. The effects of the drug, which is currently being sold under the trade name Addyi, are reportedly small: somewhere between eight and 13 percent. Secondly, its potential side effects include nausea, sleepiness, and dizziness—decidedly unsexy states of being for most of us.
Sammi Taylor 